Frontage Holdings Corp. engages in the provision of research and analytical and development services throughout the drug discovery and development process. It operates through the USA and PRC segments. The USA segment includes the bioanalytical, chemistry, manufacturing and controls (CMC), drug metabolism and pharmacokinetic (DMPK), and safety and toxicology services in the USA. The PRC segment covers the bioanalytical and bioequivalence services. The company was founded by Song Li in 2001 and is headquartered in Exton, PA.